Unknown Digestion, Kidneys & Other Organs NIHR-supported project Cancer

A phase iii, multicenter, double-blind, placebo-controlled, treat-through study to assess the efficacy and safety of induction and maintenance therapy with ro7790121 in patients with moderately to severely active crohn's disease

Funder NIHR (part of DHSC)
Recipient organisation NIHR Royal Liverpool & Broadgreen University Clinical Research Facility
NIHR support Recorded as supported by this research centre
Period Feb 2025 — Ongoing

In plain English

AI plain-English summary

A new antibody drug, RO7790121, is being tested in 600 patients across 40 countries to see if it can control moderate-to-severe Crohn’s disease better than existing treatments. Crohn’s disease is a chronic inflammatory bowel condition that causes abdominal pain, diarrhoea, and fatigue. Current drugs often lose effectiveness over time or cause serious side effects, leaving many patients without reliable long-term control. This study targets a protein called TL1A, which regulates immune responses in the gut lining and is known to drive inflammation in Crohn’s. If RO7790121 proves safe and effective, it could offer patients a new treatment option with a better benefit-risk profile. The trial includes an induction phase with intravenous infusions, followed by a maintenance phase with subcutaneous injections every four weeks for up to a year, and an optional open-label extension lasting five years. Success would mean sustained symptom control and improved long-term prognosis for people with Crohn’s, reducing hospitalisations and the need for surgery. At least 24 UK patients will take part.

View original technical description
The purpose of this study is to assess the efficacy and safety of RO7790121 in patients with moderately to severely active Crohn’s Disease (CD). RO7790121 is a monoclonal antibody TL1A which plays a central role in the regulation of gut mucosal immunity and is involved in inflammatory bowel disease.A high unmet medical need remains for treatments with better benefit-risk profiles that provide sustained control to improve the long-term prognosis of patients with CD.In this study, patients will get either the study drug or placebo.Potential participants will undergo screening tests, and if deemed eligible to take part in the study, will be randomised to a treat. group; there will be a 2 out of 3 chance of being assigned to the study drug group.The treatment part of the study will have three phases:Induction Phase - Participants will receive treatment via IV infusion on the first day of the study, then 2 weeks later, and then every 4 weeks until Week 10. Maintenance Phase - Visits approx.every 4 wks. Treatment given via subcutaneous injection every 4 weeks from the 12th week until the 52nd week of the study at a dose of either 450mg or 150mg.Open-Label Extension Phase (optional) OLE - all participants will receive the study drug (including participants who previously were given placebo). If a participant decides not to take part in the open-label extension phase of the study, they will be asked to return for three more FU visits.During the OLE phase of the study, participants will continue to have study visits and receive the study drug treatment via SC injections (given under the skin) approx. every 2-4 weeks for approx. 5 years after the last patient is enrolled in the study. Participants may have the option of being seen at home for these visits.This study will be running in approximately 40 countries with 600 patients taking part, at least 24 from the UK.The study is sponsored by F. Hoffmann- La Roche

Researchers

Violeta Razanskaite (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A Phase III, Multicenter, Double-Blind, Placebo-controlled, treat-through Study to assess the efficacy and safety of induction and Maintenance therapy with RO7790121 in patients with moderately to severely active ulcerative colitis
SIBERITE-1 - A phase iii, multicenter, double-blind, placebo-controlled, treat-through study to assess the efficacy and safety of induction and maintenance therapy with ro7790121 in patients with moderately to severely active crohn’s disease - ga45331
AMETRINE-1 A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study To Assess The Efficacy And Safety Of Induction And Maintenance Therapy With Ro7790121 In Patients With Moderately To Severely Active Ulcerative Colitis - GA45329
A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.